GLP-1, GIP and glucagon receptor agonists supporting weight loss and metabolic health. Lab tested, cold chain delivered.
Showing all 3 results
Alluvi Retatrutide 20mg – research-grade triple-agonist peptide (GLP-1, GIP, Glucagon). 20mg total active compound supplied as 4 doses of 5mg. Target pathways: GLP-1, GIP, and Glucagon receptors. Store at 2°C to 8°C. For laboratory and scientific research use only.
Alluvi Retatrutide 40mg – research-grade triple-agonist peptide (GLP-1, GIP, Glucagon). 40mg total active compound supplied as 4 doses of 10mg. Target pathways: GLP-1, GIP, and Glucagon receptors. Store at 2°C to 8°C. For laboratory and scientific research use only.
Alluvi Tirzepatide (Mounjaro) 40mg — dual-agonist research peptide targeting GLP-1 and GIP receptors. 40mg total active compound supplied as 4 doses of 10mg. 99.85% purity, Janoshik Analytical tested, batch COA available. Cold-chain UK delivery. For laboratory and scientific research use only.
No products in the basket.
